Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate (original) (raw)

• Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572.
  Article CAS PubMed Google Scholar
• Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans -retinoic acid). N Engl J Med 1991; 324: 1385–1393.
  Article PubMed Google Scholar
• Ohno R, Yoshida H, Fukutani H, Naoe T, Ohshima T, Kyo T et al. Multi-institutional study of all-_trans_-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 722–727.
  Google Scholar
• Fenaux P, Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241–3249.
  Article CAS PubMed Google Scholar
• Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1993; 82: 2175–2181.
  Article Google Scholar
• Kanamaru A, Takemoto N, Tanimoto M, Murakami H, Asou N, Kobayashi T et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202–1206.
  Article CAS PubMed Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-_trans_-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.
  Article CAS PubMed Google Scholar
• Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014–1021.
  CAS PubMed Google Scholar
• Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78–85.
  Article CAS PubMed Google Scholar
• Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–4143.
  Article CAS PubMed Google Scholar
• Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all _trans_retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.
  Article CAS PubMed Google Scholar
• Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000; 14: 1371–1377.
  Article CAS PubMed Google Scholar
• Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. Blood 1999; 94: 3015–3021.
  CAS PubMed Google Scholar
• Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000; 14: 1362–1370.
  Article CAS PubMed Google Scholar
• Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia: the APL92 study Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 2001; 48 (Suppl 1) S65–S71.
  Article PubMed Google Scholar
• Lo Coco F, Nervi C, Avvisati G, Mandelli F . Acute promyelocytic leukemia: a curable disease. Leukemia 1998; 12: 1866–1880.
  Article CAS PubMed Google Scholar
• Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
  Article CAS PubMed Google Scholar
• Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968–973.
  CAS PubMed Google Scholar
• Michieli M, Damiani D, Ermacora A, Geromin A, Michelutti A, Masolini P et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol 2000; 108: 703–709.
  Article CAS PubMed Google Scholar
• Takeshita A, Shinjo K, Naito K, Ohnishi K, Sugimoto Y, Yamakawa Y et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000; 108: 90–92.
  Article CAS PubMed Google Scholar
• Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100: 3141–3146.
  Article CAS PubMed Google Scholar
• Gallagher RE . Retinoic acid-resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940–1958.
  Article CAS PubMed Google Scholar
• Jansen JH, de Ridder MC, Geertsma WM, Erpelinck CA, van Lom K, Smit EM et al. Complete remission of t(11; 17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 1999; 94: 39–45.
  Article CAS PubMed Google Scholar
• Culligan DJ, Stevenson D, Chee YL, Grimwade D . Acute promyelocytic leukaemia with t(11; 17)(q23; q12-21) and a good initial response to prolonged ATRA and combination chemotherapy. Br J Haematol 1998; 100: 328–330.
  Article CAS PubMed Google Scholar
• Petti MC, Fazi F, Gentile M, Diverio D, De Fabritiis P, De Propris MS et al. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 2002; 100: 1065–1067.
  Article CAS PubMed Google Scholar
• Di Bona E, Avvisati G, Castaman G, Luce Vegna M, De Sanctis V, Rodeghiero F et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108: 689–695.
  Article CAS PubMed Google Scholar
• Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N . All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994; 84: 3001–3009.
  Article CAS PubMed Google Scholar
• Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA . Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994–1004.
  Article CAS PubMed Google Scholar
• Barbui T, Finazzi G, Falanga A . The impact of all-_trans_-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093–3102.
  Article CAS PubMed Google Scholar
• Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell Jr RP . The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292.
  Article CAS PubMed Google Scholar
• De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R et al. Incidence, clinical features, and outcome of all _trans_-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712–2718.
  Article CAS PubMed Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90–95.
  CAS PubMed Google Scholar
• Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18: 2620–2625.
  Article CAS PubMed Google Scholar
• Tallman MS . Retinoic acid syndrome: a problem of the past? Leukemia 2002; 16: 160–161.
  Article CAS PubMed Google Scholar
• Wiley JS, Firkin FC . Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995; 9: 774–778.
  CAS PubMed Google Scholar
• Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014–1021.
  CAS PubMed Google Scholar
• Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ trial. Blood 1998; 92: 784–789.
  Article CAS PubMed Google Scholar
• Warrell Jr RP . Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993; 82: 1949–1953.
  Article CAS PubMed Google Scholar
• Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172–1183.
  Article CAS PubMed Google Scholar
• Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K . Retinobenzoic acids. 1. Structure–activity relationships of aromatic amides with retinoidal activity. J Med Chem 1988; 31: 2182–2192.
  Article CAS PubMed Google Scholar
• Hashimoto Y, Kagechika H, Kawachi E, Fukazawa H, Saito G, Shudo K . Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB-4. J Cancer Res Clin Oncol 1995; 121: 696–698.
  Article CAS PubMed Google Scholar
• Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997; 90: 967–973.
  Article CAS PubMed Google Scholar
• Shinjo K, Takeshita A, Ohnishi K, Sakura T, Miyawaki S, Hiraoka A et al. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-_trans_-retinoic acid. Int J Hematol 2000; 72: 470–473.
  CAS PubMed Google Scholar
• Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 2230–2235.
  Article CAS PubMed Google Scholar
• Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, Boehm K et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97: 73–80.
  Article CAS PubMed Google Scholar
• Soignet SL, Benedetti F, Fleischauer A, Parker BA, Truglia JA, Ra Crisp M et al. Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia. Leukemia 1998; 12: 1518–1521.
  Article CAS PubMed Google Scholar
• Sun HD, Ma L, Hu XC, Zhang TD, Rong FX, Wang XH et al. Sixteen cases of long-term survivors with acute promyelocytic leukemia treated with traditional Chinese medicine, Ailin No. 1. Informat Tradition Chin Med 1991 (Chinese); 6: 39.
  Google Scholar
• Sun HD, Ma L, Hu XC, Zhang TD . Treatment of 32 cases of acute promyelocytic leukemia with traditional Chinese medicine, Ailin No.1. Chin J Integrat Chin West Med 1992 (Chinese); 12: 170–171.
  Google Scholar
• Zhang P, Wang SY, Hu LH, Shi FD, Qiu FQ, Hong GJ et al. Treatment of 72 cases of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol 1996 (Chinese with English abstract); 2: 58–59.
  Google Scholar
• Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360.
  Article CAS PubMed Google Scholar
• Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348.
  Article CAS PubMed Google Scholar
• Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133: 881–885.
  Article CAS PubMed Google Scholar
• Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514–1516.
  Article CAS PubMed Google Scholar
• Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266–271.
  Article CAS PubMed Google Scholar
• Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103: 1092–1095.
  Article CAS PubMed Google Scholar
• Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617–622.
  Article CAS PubMed Google Scholar
• Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
  Article CAS PubMed Google Scholar
• Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.
  Article CAS PubMed Google Scholar
• Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136–3143.
  Article CAS PubMed Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.
  Article CAS PubMed Google Scholar
• Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 2001; 115: 63–65.
  Article CAS PubMed Google Scholar
• Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH et al. Experience with gemtuzumab ozogamycin (‘mylotarg’) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222–4224.
  Article CAS PubMed Google Scholar
• Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA .Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372–380.
  CAS PubMed Google Scholar
• Warrell Jr RP, He LZ, Richon V, Calleja E, Pandolfi PP . Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621–1625.
  Article CAS PubMed Google Scholar
• Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM . Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811–814.
  Article CAS PubMed Google Scholar
• Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447–1452.
  Article CAS PubMed Google Scholar
• Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185–2189.
  Article CAS PubMed Google Scholar
• Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100: 2941–2949.
  Article CAS PubMed Google Scholar
• Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485–1492.
  Article CAS PubMed Google Scholar
• Byrd JC, Edenfield WJ, Shields DJ, Dawson NA . Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995; 13: 1800–1816.
  Article CAS PubMed Google Scholar
• Giralt S, O'Brien S, Weeks E, Luna M, Kantarjian H . Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma 1994; 14: 453–456.
  Article CAS PubMed Google Scholar
• Weiss MA, Warrell Jr RP . Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer 1994; 74: 1882–1886.
  Article CAS PubMed Google Scholar
• Tobita T, Shinjyo K, Yanagi M, Takeshita A, Ohnishi K, Ohno R . Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid. Intern Med 1997; 36: 484–486.
  Article CAS PubMed Google Scholar
• Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001; 19: 4023–4028.
  Article CAS PubMed Google Scholar
• Breccia M, Petti MC, Testi AM, Specchia G, Ferrara F, Diverio D et al. Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated ‘sanctuary’? Leukemia 2002; 16: 1127–1130.
  Article CAS PubMed Google Scholar
• Hickstein DD, Hickey MJ, Collins SJ . Transcriptional regulation of the leukocyte adherence protein beta subunit during human myeloid cell differentiation. J Biol Chem 1988; 263: 13863–13867.
  Article CAS PubMed Google Scholar
• Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M et al. Therapy-related myelodysplastic syndrome – acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822–824.
  Article CAS PubMed Google Scholar
• Sanz MA, Arcese W, de la Rubia J, Lo Coco F, Labopin M, Bacigalupo A et al. Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: a survey of the European Blood and Marrow Transplantation Group (EBMT) [abstract]. Blood 2000; 96: 2246.
  Article Google Scholar
• Collins SJ . Acute promyelocytic leukemia: relieving repression induces remission. Blood 1998; 91: 2631–2633.
  Article CAS PubMed Google Scholar
• Strudwick S, Borden KLB . Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia 2002; 16: 1906–1917.
  Article CAS PubMed Google Scholar
• Ferbeyre G . PML a target of translocations in APL is a regulator of cellular senescence. Leukemia 2002; 16: 1918–1926.
  Article CAS PubMed Google Scholar
• Lutz PG, Moog-Lutz C, Cayre YE . Signaling revisited in acute promyelocytic leukemia. Leukemia 2002; 16: 1933–1939.
  Article CAS PubMed Google Scholar
• Grimwade David, Lo Coco F . Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959–1973.
  Article CAS PubMed Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
  Article CAS PubMed Google Scholar
• Takeshita A, Sakamaki H, Miyawaki S, Kobayashi T, Kuriyama K, Yamada O et al. Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. Cancer 1995; 76: 602–608.
  Article CAS PubMed Google Scholar